Bellecapital International Ltd. Takes Position in Novartis AG (NYSE:NVS)

Bellecapital International Ltd. purchased a new stake in Novartis AG (NYSE:NVSFree Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 917 shares of the company’s stock, valued at approximately $93,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NVS. Moneta Group Investment Advisors LLC raised its position in shares of Novartis by 102,209.0% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 4,522,057 shares of the company’s stock valued at $410,241,000 after buying an additional 4,517,637 shares in the last quarter. Grantham Mayo Van Otterloo & Co. LLC raised its position in shares of Novartis by 167.6% in the third quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,827,263 shares of the company’s stock valued at $186,125,000 after buying an additional 1,144,307 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Novartis by 103.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,992,558 shares of the company’s stock valued at $174,847,000 after buying an additional 1,010,806 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Novartis by 50.4% in the third quarter. Envestnet Asset Management Inc. now owns 2,049,901 shares of the company’s stock valued at $208,803,000 after buying an additional 686,847 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Novartis by 27.2% in the first quarter. Goldman Sachs Group Inc. now owns 2,781,596 shares of the company’s stock valued at $244,085,000 after buying an additional 594,194 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Stock Up 0.9 %

Shares of NYSE:NVS opened at $96.73 on Monday. The company has a fifty day moving average of $101.31 and a 200-day moving average of $99.73. The company has a market capitalization of $205.03 billion, a PE ratio of 13.47, a price-to-earnings-growth ratio of 1.50 and a beta of 0.54. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.93 and a current ratio of 1.15. Novartis AG has a 52-week low of $89.81 and a 52-week high of $108.78.

Novartis (NYSE:NVSGet Free Report) last announced its quarterly earnings results on Tuesday, January 30th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Novartis had a return on equity of 29.90% and a net margin of 29.83%. The company had revenue of $11.42 billion for the quarter, compared to analyst estimates of $11.69 billion. During the same quarter last year, the company posted $1.51 earnings per share. On average, equities analysts predict that Novartis AG will post 7.17 EPS for the current fiscal year.

Novartis Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, March 7th. Investors of record on Friday, March 8th were paid a $3.7772 dividend. This is a boost from Novartis’s previous annual dividend of $3.47. The ex-dividend date of this dividend was Thursday, March 7th. This represents a dividend yield of 3.1%. Novartis’s payout ratio is currently 34.26%.

Wall Street Analysts Forecast Growth

NVS has been the subject of several research analyst reports. StockNews.com initiated coverage on shares of Novartis in a research report on Wednesday, December 6th. They set a “strong-buy” rating for the company. HSBC downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research report on Monday, December 18th. BMO Capital Markets initiated coverage on shares of Novartis in a research report on Friday, February 23rd. They set a “market perform” rating and a $114.00 price objective for the company. Finally, Morgan Stanley initiated coverage on shares of Novartis in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $114.00 price objective for the company. Three analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $104.33.

Get Our Latest Stock Report on NVS

Novartis Company Profile

(Free Report)

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Featured Stories

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVSFree Report).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.